Early research (Phase 1)Not Yet RecruitingNCT06385522
What this trial is testing
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Who this might be right for
NHLCutaneous T Cell LymphomaPeripheral T-cell Lymphoma
Boston Immune Technologies and Therapeutics 37